Grid Therapeutics

Grid Therapeutics is a biotech company based on the innovative science first developed by Edward F. Patz, Jr. MD and his team of scientists at Duke University Medical Center. Located in Durham, North Carolina, Grid is developing the first human derived targeted immunotherapy for cancer. The antibody was discovered in exceptional outcome early stage lung cancer patients who did not progress to develop metastasis. The antibody was isolated from patient's B-cells using state of the art molecular genomic techniques. "GT103", the company's lead asset, is currently enrolling the first-in-man Phase 1 clinical trial in refractory NSCLC patients.